EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.
Key facts
- Where
- Hong Kong, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05597488, who can take part
Where in China
- Chinese University of Hong KongHong Kong, ChinaContact: Anthony Y Teoh, FRCSEd(Gen)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT05597488
- Record updated
- 20 March 2026
- Original description
The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis. The hypothesis is that a high EUS-PPGM value at 3 months correlates with the presence of varices requiring EVL in patients that have received primary or secondary variceal prophylaxis on 1 year follow-up upper endoscopy.Read full original descriptionShow less
The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis. The hypothesis is that a high EUS-PPGM value at 3 months correlates with the presence of varices requiring EVL in patients that have received primary or secondary variceal prophylaxis on 1 year follow-up upper endoscopy.
Inclusion: Age between 18 to 75 years old; Informed consent available; Suffering from chronic hepatitis induced cirrhosis; Suffering from oesophageal varices and received EVL as a result of; Primary variceal prophylaxis during a variceal surveillance program on oesophagogastroduodenoscopy (OGD) or; Secondary variceal prophylaxis after EVL in patients with active oesophageal variceal bleeding; Or bleeding gastric varices that have received endoscopic canoacrylate injection.
Exclusion: Anatomical Main portal vein thrombosis Anatomic alterations of the hepatic vasculature that prevent access to the portal vein or intrahepatic portion of the hepatic veins (identified at screening and/or during the endoscopic procedure); Previous history of spontaneous bacterial peritonitis within the previous three months Portopulmonary hypertension Cardiac decompensation; Endoscopically Confirmed Exclusion Criteria Presence of ascites in the path of the needle that prevents apposition of the gastrointestinal tract and liver; Presence of gastric or duodenal ulcers, dieulafoy's lesion or cancers; Medical Child-Pugh Class C Uncorrected platelet count <50,000 INR > 1.5 (natural) History of hepatic encephalopathy Current or history of hepatocellular carcinoma.